Nexus Surgical and Medicare Ratios

Nexus Surgical and Medicare Ltd Ratios

The Nexus Surgical and Medicare Ltd Ratios page provides a complete fundamental analysis of Nexus Surgical and Medicare Ltd using key valuation, profitability, and financial strength metrics. Investors tracking Nexus Surgical and Medicare Ltd Ratios closely monitor D/E, EV, EV/EBITDA, P/B, P/CF, P/E, P/S, and ROE% to evaluate the company's financial performance and valuation trends over time.

Nexus Surgical and Medicare Ltd (NSE: , BSE: 538874) is currently trading at ₹17.52, with a market capitalization of ₹95.87M. As a major player in the Distribution services sector and Medical distributors industry, Nexus Surgical and Medicare Ltd remains a key stock for fundamental analysis using Nexus Surgical and Medicare Ltd Ratios.

Nexus Surgical and Medicare Ltd Ratios: Valuation Overview

Price to Earnings Ratio (P/E)

The Nexus Surgical and Medicare Ltd P/E ratio currently stands at 18.14, making it one of the most tracked metrics in Nexus Surgical and Medicare Ltd Ratios.

Historically, the Nexus Surgical and Medicare Ltd P/E ratio has shown strong fluctuations:

• 2024: 18.14
• 2023: 34.58
• 2022: 27.72
• 2021: 14.22
• 2020: 12.26

The decline in Nexus Surgical and Medicare Ltd P/E ratio suggests improving earnings relative to stock price.

Price to Book Ratio (P/B)

The Nexus Surgical and Medicare Ltd P/B ratio reflects how the market values the company's net assets. Current P/B ratio is 8.48.

Historical P/B trend:

• 2024: 8.48
• 2023: 13.03
• 2022: 13.41
• 2021: 22.64

Nexus Surgical and Medicare Ltd is trading at a premium to its book value, indicating strong market confidence.

Price to Sales Ratio (P/S)

The Nexus Surgical and Medicare Ltd P/S ratio currently stands at 1.58, an important part of Nexus Surgical and Medicare Ltd Ratios for revenue valuation.

Historical P/S ratio:

• 2024: 1.58
• 2023: 2.12
• 2022: 3.05
• 2021: 1.72

A stable or declining Nexus Surgical and Medicare Ltd P/S ratio indicates cautious market sentiment.

Nexus Surgical and Medicare Ltd Price to Cash Flow Ratio (P/CF)

The Nexus Surgical and Medicare Ltd Price to Cash Flow Ratio is a key valuation metric that shows how much investors pay for each unit of cash flow. Current P/CF ratio is 86.55.

Historical Nexus Surgical and Medicare Ltd Price to Cash Flow Ratio:

• 2024: 86.55
• 2023: 0
• 2022: 8.61
• 2021: 0
• 2020: 9.51

The rising Nexus Surgical and Medicare Ltd Price to Cash Flow Ratio indicates premium valuation based on cash flow.

Nexus Surgical and Medicare Ltd Enterprise Value Ratios

Enterprise Value (EV)

The Nexus Surgical and Medicare Ltd EV currently stands at ₹86.92M, representing the total company valuation including debt.

Historical EV trend:

• 2024: 86.92M
• 2023: 71.42M
• 2022: 40.82M
• 2021: 40.18M

Nexus Surgical and Medicare Ltd enterprise value shows long-term growth, reflecting expansion and market confidence.

EV/EBITDA Ratio

The Nexus Surgical and Medicare Ltd EV/EBITDA ratio is currently 12.41, a key metric in Nexus Surgical and Medicare Ltd Ratios to assess valuation relative to earnings.

Historical EV/EBITDA:

• 2024: 12.41
• 2023: 24.23
• 2022: 18.74
• 2021: 10.88

Stable Nexus Surgical and Medicare Ltd EV/EBITDA indicates balanced valuation.

Nexus Surgical and Medicare Ltd Financial Strength Ratios

Debt to Equity Ratio (D/E)

The Nexus Surgical and Medicare Ltd D/E ratio is currently 0, reflecting leverage and financial stability.

Historical D/E:

• 2024: 0
• 2023: 0
• 2022: 0
• 2021: 0

Nexus Surgical and Medicare Ltd maintains a strong balance sheet with low debt levels.

Return on Equity (ROE %)

The Nexus Surgical and Medicare Ltd ROE currently stands at 61.03%, showing profitability and capital efficiency.

Historical ROE:

• 2024: 61.03
• 2023: 46.41
• 2022: 63.79
• 2021: 781.37

Nexus Surgical and Medicare Ltd demonstrates strong profitability and efficient capital utilization.

Nexus Surgical and Medicare Ltd Ratios Analysis Summary

The Nexus Surgical and Medicare Ltd Ratios page provides a comprehensive view of the company's valuation and financial performance. Key metrics such as P/E, P/B, P/S, P/CF, EV, EV/EBITDA, D/E, and ROE help investors understand whether Nexus Surgical and Medicare Ltd stock is undervalued, fairly valued, or overvalued.

Tracking Nexus Surgical and Medicare Ltd Ratios regularly helps investors make informed decisions based on valuation trends, financial stability, and long-term growth potential.